disagreements on price and concerns expressed by baxalta shareholders. if you look over last week, ariad has given back all of the gains since last week when both bloomberg and we reported that baxalta approached aria. i learned the initial approach was i month ago and ariad did reject that. as for baxalta it of course is fending off a $30 billion bid from shire. and i'm actually told that shire itself if it doesn't get this deal done could itself be a target for bigger companies like allergan. so it's this continuation of pac man type deals in the pharma space. for ariad it's not inconceivable it could be a takeover target for baxalta or others. it's got an approved cancer drug on the market forecast to do about $130 million this year in sales. it's got a lung cancer drug in late-stage trials in the pipeline. so both things that make it potentially attractive to acquirers. if you look there at the chart we have of baxalta and shire you can see shire's stock has lost 15% in the last month since it made its initial all-stock offer. that's fallen quite a b

if david were here, i'm sure he'd have thoughts on that. >> baxalta, they got a bid. lot of companies got bids. you had a stat the other day, $180 billion in m&a, the most ever. >> in 2000. >> and the last few have been fought. and i know there are people who are shareholders who are saying we're in a bear market and you're turning down bids? you're issuing stock in are you out of your mind? we want to take the money and run. i've been watching perrigo. it's a great company. there are people who say i don't care that the earnings are good and the p/e is shrinking. people want their bids, and they're not happy, because the market is so bad. without a bid or propup, some of the stocks would go down as much as they're going down that don't have bids. let's get to bob. >> essentially at the highs for the day. global markets stable. the dollar is firmer. take a look at the s&p futures. the productivity report helped. better than expected. we had a nice pop up around that time. about ten points. that helped out. good news on the economy, generally. sectors, all ten sectors

shire considering options for baxalta.re is weighing putting cash into shareholders hands sooner. shire has an unsolicited stock holding last month at $36 billion based on shire's stock price at the time. the lack of cash was to maintain the tax status. shire promised a share buy back program after the close of that deal. >>> also solera holdings going higher. they were bought for $3.7 billion. that's a 13% premium to friday's closing price. >>> let us check on the markets this morning. we had a huge horrific selloff in china but we're okay. so far off 55 points or so on the session. that has to do with europe taking it in stride with what we saw even further east. the dow jones up 54. the s&p up 56 and a half. europe is mixed. italy and greece trading earlier. look at the asian markets. there's shanghai which is down 3%. it was i think worse. i think it pared its losses going into the close which indicates there may have been government support. we can't check on a daily basis. it was worse than that earlier. going to be